Phase I Study Websites
Apogenix ǀ Immuno-oncology therapeutics for the treatment of cancer an
Apogenix develops innovative protein therapeutics for the treatment of cancer and other malignant diseases. Our lead drug candidate APG101 has demonstrated a statistically significant efficacy in a controlled phase II trial in recurrent glioblastoma.
3,446,235
$
480.00
